KRAS and neoplasm: Previous studies have implicated the dose of mutant Kras in tumor progression, cell motility, and metabolic reprogramming18,19,29, therefore we used the GFP-labeled eye expression system to clonally express RasHigh and mutate Lkb1 in developing eye epithelia (RasHigh/Lkb1−/−).